Raymond Cheong
Director/Board Member at TALIS BIOMEDICAL CORPORATION
Net worth: - $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Friedman | M | 81 | 8 years | |
| Fred Craves | M | 78 | 13 years | |
| Richard Nelson | M | 54 | 4 years | |
| William Sibold | M | - | 1 years | |
| Rebecca Taub | M | 71 | 8 years | |
| Robert Kelley | M | 52 | 4 years | |
| Kim Popovits | F | 65 | 4 years | |
| Edward Chiang | M | - | 13 years | |
| Paul Sekhri | M | 65 | 2 years | |
| Rebecca Markovich | F | 51 | 2 years | |
| Jill Green | F | - | 4 years | |
| Dani Paul Bolognesi | M | - |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | - |
| Richard Levy | M | 66 | 8 years | |
| Randal Scott | M | 66 | 10 years | |
| Matthew Posard | M | 56 | 8 years | |
| Heiner Dreismann | M | 69 | 1 years | |
| Rustem Ismagilov | M | 50 | 11 years | |
| James Daly | M | 63 | 5 years | |
| Emily Faucette | F | - | 3 years | |
| Ken Bate | M | 73 | 8 years | |
| Julian Baker | M | 57 | 1 years | |
| Fahed Al Marzooqi | M | 45 | 2 years | |
| Vanessa McDade | F | - | - | |
| Jennifer Freeman | F | - | - | |
| Robert R. Bonczek | M | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | - |
| Steven Tuch | M | 56 | 2 years | |
| Matthew Pepe | M | - | 3 years | |
| Barry Brown | M | 63 | 2 years | |
| Gillian Green | F | - | - | |
| Carole Huntsman | F | - | - | |
| Stephen Dodge | M | - | - | |
| Christopher Frates | M | - | 3 years | |
| Dominic F. Labriola | M | - | 2 years | |
| Robert Waltermire | M | 60 | 3 years | |
| Mark Barrett | M | - | - | |
| Tina Ventura | F | - | - | |
| Sean Nolan | M | 56 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 6 years |
| Thomas Strack | M | - | 1 years | |
| Elizabeth M. Keiley | F | 58 | 1 years | |
| Victor Sandor | M | 57 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 5 years |
| Carmen Valcarce | M | - | 17 years | |
| Srini Akkaraju Akkaraju | M | 56 | - | |
| Brian Lynch | M | 62 | 5 years | |
| Ronald Filippo | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian J. Blaser | M | 59 | - | |
| Brian Coe | M | 55 | - | |
| David Milligan | M | 83 | 7 years | |
| Howard Weiner | M | 78 | 7 years | |
| Hersh Kozlov | M | 76 | 5 years | |
| John Fry | M | 64 | 8 years | |
| Keith Harris | M | 71 | 2 years | |
| Keith Gollust | M | 78 | 7 years | |
| Alex Howarth | M | 55 | 3 years | |
| Felix Baker | M | 55 | 10 years | |
| Jonathan Isaacsohn | M | 70 | 2 years | |
| Melissa Gilliam | M | 58 | 3 years | |
| Andrew Lukowiak | M | 52 | 1 years | |
| Shannon Morris | M | 54 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 2 years |
| Ramesh Ramakrishnan | M | 64 | 2 years | |
| Karen E. Flick | M | 54 | 6 years | |
| Douglas Liu | M | 62 | 2 years | |
| Remy Sukhija | M | 52 | 3 years | |
| Kianoush Motesharei | M | 54 | - | |
| Jeryl Hilleman | F | 66 | 1 years | |
| William Nichols | M | 55 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 2 years |
| John Roger Moody | M | 56 | 3 years | |
| Daisy Joe Du Bois | M | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 67 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Raymond Cheong
- Personal Network
